Former Senior Vice President, Chief Operations Officer · Anika Therapeutics, Inc. (ANIK)

Anne Nunes

FY2025 is the first fiscal year CompBrief holds for Anne Nunes as a named executive officer of Anika Therapeutics; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2025

$946,571

Compensation figures as of the proxy filed April 28, 2026 (DEF 14A).

Anne Nunes compensation by year

Anika Therapeutics Summary Compensation Table · the one fiscal year held
In US dollars, as Anika Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2025
Salary$157,639
Bonus$0
Stock awards$505,922
Option awards$0
Non-equity incentive$0
Pension and deferred compensation$0
All other$282,310
Total$946,571

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Anika Therapeutics, Inc. DEF 14A filed April 28, 2026, accession 0001140361-26-017488, and prior-year filings. Open the filing on EDGAR.

Anika Therapeutics’s named executive officers, FY2025

as the company reported each
Named executive officerRoleFY2025 total
Cheryl BlanchardExecutive Chair; Former President and Chief Executive Officer$4,887,318
Stephen GriffinPresident and Chief Executive Officer; Former EVP, Chief Financial Officer and Chief Operating Officer$2,033,370
David ColleranExecutive Vice President, General Counsel and Secretary$1,614,205
Anne Nunes · this pageFormer Senior Vice President, Chief Operations Officer$946,571
Ian McLeodSenior Vice President, Chief Accounting Officer and Treasurer$765,544

The full Anika Therapeutics compensation record

free company brief

This page is one person within Anika Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Anika Therapeutics's full Executive Compensation Report with peer benchmarking.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Anika Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Velarion Pro: every company page, peer tools and exports, one seat

One email to you when Pro opens, and nothing else. Privacy